FILING ANALYSIS · MONDAY, NOVEMBER 16
ALX ONCOLOGY HOLDINGS INC ALXO — 8-K: Results of Operations and Financial Condition
neutral
The company reported Q3 financial results with cash and equivalents of $147.2 million, which is expected to fund operations through the first half of 2028, and announced expectations for topline data from clinical trials, including the ASPEN-09-Breast trial in 2H 2027 and ALX2004 Phase 1 trial data in December 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →